New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan

Nakagawa, Naoki; Maruyama, Shoichi; Kashihara, Naoki; Narita, Ichiei; Isaka, Yoshitaka

doi:10.1007/s10157-022-02231-y

Cited by 6 publications

(13 citation statements)

References 26 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date (July 2022), there are in the literature 66 cases of NS “de novo” or relapses that occurred in concomitance, or near to, the administration of a mRNA vaccine, where concomitance is defined as NS occurring within 1 month after vaccination [ 74 – 89 ]. The numerically most significant study (27 cases) was undertaken in Japan as part of a web-based survey within council members of the Japanese Society of Nephrology [ 89 ]. This study included children and adults with relapse and de novo NS with variable pathologic characteristics (12 MCD, 4 membranous nephropathy, 2 FSGS, 2 IgA nephropathy and various other cases).…”

Section: Resultsmentioning

confidence: 99%

“…To date (July 2022), there are in the literature 66 cases of NS "de novo" or relapses that occurred in concomitance, or near to, the administration of a mRNA vaccine, where concomitance is defined as NS occurring within 1 month after vaccination [74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89]. The numerically most significant study (27 cases) was undertaken in Japan as part of a webbased survey within council members of the Japanese Society of Nephrology [89]. This study included children and adults with relapse and de novo NS with variable pathologic characteristics (12 MCD, 4 membranous nephropathy, 2 FSGS, 2 IgA nephropathy and various other cases).…”

Section: Sars-cov-2 Mrnamentioning

confidence: 99%

“…Among the 6 cases of NS associated with the Moderna mRNA 1273 vaccine, 4 were "de novo" NS and 2 were relapses. Complete remission was obtained with steroids alone (5) or in association with MMF (2) (Table 4) [82][83][84]89].…”

Section: Sars-cov-2 Mrnamentioning

confidence: 99%

See 2 more Smart Citations

Vaccines and nephrotic syndrome: efficacy and safety

et al. 2022

View full text Add to dashboard Cite

Vaccines represent the most important medical evolution in the last two centuries allowing prevention and formally eradication of a wide number of infectious diseases. Safety and effectiveness are main issues that still require an open discussion. A few clinical reports described a critical temporal relationship between vaccination and acute nephrotic syndrome, indirectly suggesting an association. For this review, the literature was reviewed to identify articles reporting associations of nephrotic syndrome with vaccines against a vast array of infectious diseases (including bacteria, virus and Sars-Cov-2). As specific aims, we evaluated effectiveness and safety in terms of occurrence of either “de novo” nephrotic syndrome in health subjects or “relapse” in those already affected by the disease. In total, 377 articles were found; 166 duplicates and 71 non-full text, animal studies or non-English language were removed. After excluding another 50 articles not containing relevant data on generic side effects or on relapses or new onset nephrotic syndrome, 90 articles met the search criteria. Overall, studies reported the effect of vaccines in 1015 patients, plus 4 nationwide epidemiologic investigations. Limited experience on vaccination of NS patients with measles, mumps, and rubella live attenuated vaccines does not allow any definitive conclusion on their safeness. VZV has been administered more frequently without side effects. Vaccines utilizing virus inactivated, recombinant, and toxoid can be utilized without risks in NS. Vaccines for influenza reduce the risk of infections during the pandemic and are associated with reduced risk of relapse of NS typically induced by the infection. Vaccines for SARS-CoV-2 (all kinds) offer a concrete approach to reduce the pandemic. “De novo” NS or recurrence are very rare and respond to common therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Sars-cov-2 Mrnamentioning

confidence: 99%

See 1 more Smart Citation

Vaccines and nephrotic syndrome: efficacy and safety

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recurrence of ulcerative colitis, 20 glomerulonephritis, 21 multiple sclerosis, 22 nephrotic syndrome, 23 uveitis, 24 and Vogt–Koyanagi–Harada (VKH) disease 25 may be associated with vaccination against SARS-CoV-2. Masuta et al.…”

Section: Discussionmentioning

confidence: 99%

Possible association between vaccination against SARS-CoV-2 and recurrence of macular edema due to branch retinal vein occlusion: a case report

Muto,

Machida,

Imaizumi

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

We herein describe a patient who developed recurrence of macular edema (ME) due to branch retinal vein occlusion (BRVO) 3 days after administration of the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A man in his early 50s visited our hospital because of vision loss in his right eye. His logarithmic best-corrected visual acuity (BCVA) was −0.79 in both eyes. ME due to superior temporal BRVO was observed in his right eye, and the central foveal thickness (CFT) was 486 µm. The patient was treated with an intravitreal aflibercept injection with logarithmic BCVA of −0.79, leading to resolution of the ME with a CFT of 299 µm. Three months after the initial visit, he received a fourth dose of an mRNA vaccine. Three days later, he developed vision loss in his right eye. Although the logarithmic BCVA was maintained at −0.79, ME recurred with a CFT of 507 µm. The patient was treated with an additional dose of intravitreal aflibercept injection. The ME resolved and the logarithmic BCVA in the right eye was maintained at −0.79. This case indicates a possible association between vaccination against SARS-CoV-2 and recurrence of ME due to BRVO.

show abstract

“…Reports of de novo and relapses of glomerular disease (GD) temporally associated with COVID-19 vaccination (termed CVAGD for COVID-19 vaccine–associated GD) began to emerge by mid-2021 with an increasing number of reports published. 2-27 To date, a cause-effect relationship has not been established. Given the relative rarity of these events and limited follow-up, we created an International Registry of COVID-19 vaccination and Glomerulonephritis to collect consistent data on potential cases of CVAGD to analyze in aggregate.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry

Waldman¹,

Sinaii

Lerma

et al. 2023

Kidney360

View full text Add to dashboard Cite

Background:Cases of de novo glomerular disease with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established and the long-term outcomes are not known. To better characterize the glomerular diseases and clinical course/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis (IRocGN2) to study in aggregate de novo glomerulonephritis cases suspected after COVID-19 vaccine exposure Methods:A RedCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and glomerular disease histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes. Results: Ninety-eight glomerular disease cases were entered into the registry over eleven months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most the common kidney diseases reported. Recovery of kidney function and remission of proteinuria was more likely in IgAN and MCD at 4-6 months than with pauci immune glomerulonephritis /vasculitis and membranous nephropathy. Conclusions:Development of glomerular disease after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment is recommended based on these findings.

show abstract

New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan

Cited by 6 publications

References 26 publications

Vaccines and nephrotic syndrome: efficacy and safety

Vaccines and nephrotic syndrome: efficacy and safety

Possible association between vaccination against SARS-CoV-2 and recurrence of macular edema due to branch retinal vein occlusion: a case report

COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry

Contact Info

Product

Resources

About